We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies. In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Recursion (RXRX) Up on Completing REC-994 Study Enrollment
Read MoreHide Full Article
Recursion (RXRX - Free Report) announced full patient enrollment in its phase II SYCAMORE study evaluating REC-994 to treat cerebral cavernous malformations (CCM). Shares of the company were up 3.12% on Jun 13, after market hours, on the news.
REC-994 is an orally bioavailable small molecule, designed specifically for the treatment of CCM. The mid-stage study is being conducted at multiple centers, where patients have been randomly assigned to different groups to test the safety and effectiveness of REC-994.
The primary endpoint of the study is to assess the safety and tolerability of the candidate by measuring adverse events.
The secondary endpoint is to determine the effectiveness of REC-994 by considering feedback from both doctors and patients, conducting imaging tests to measure the number, size and changes in CCM lesions, studying the impact of acute stroke and exploring different biomarkers. These comprehensive assessments will provide valuable insights about REC-994’s potential as a treatment for CCM.
CCM is a neurovascular disorder triggered by genetic mutations, either inherited or acquired, impacting the functions of endothelial cells. The disease is marked by weak and thin blood vessel walls that can result in blood leakage into the surrounding brain or spinal cord tissue. This leakage can cause damage to the nearby brain tissue and result in persistent neurological issues. In rare instances, a more severe bleeding episode can lead to a stroke or even death.
Shares of Recursion have risen 28.9% year to date against the industry’s 1.3% decline.
Image Source: Zacks Investment Research
If successfully developed, REC-994 will have a market to address approximately 360,000 patients in Europe and the United States.
REC-994 has been granted the Orphan Drug designation for CCM by the FDA and the European Commission. This designation provides the company with additional market exclusivity and expedited regulatory paths.
Recursion’s other clinical studies include REC-2282 and REC-4881 for the potential treatment of neurofibromatosis and familial adenomatous polyposis, respectively. Both candidates are currently in the mid-stage clinical study.
Recursion Pharmaceuticals, Inc. Price and Consensus
Loss per share estimate for Akero Therapeutics has narrowed from $3.46 to $2.80 for 2023 in the past 90 days. Shares of Akero Therapeutics have risen 3.8% year to date.
AKRO’s earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 7.96%.
Loss per share estimate for ADMA Biologics has narrowed from 19 cents to 9 cents for 2023 in the past 90 days. Shares of ADMA Biologics have nosedived 3.1% year to date.
ADMA’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.13%.
Loss per share estimate for Omega Therapeutics has narrowed from $2.51 to $2.05 for 2023 in the past 90 days. Shares of the company have risen 41.8% year to date.
OMGA’s earnings beat estimates in two of the trailing four quarters, met the mark in one and missed in another, delivering an average surprise of 8.24%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Recursion (RXRX) Up on Completing REC-994 Study Enrollment
Recursion (RXRX - Free Report) announced full patient enrollment in its phase II SYCAMORE study evaluating REC-994 to treat cerebral cavernous malformations (CCM). Shares of the company were up 3.12% on Jun 13, after market hours, on the news.
REC-994 is an orally bioavailable small molecule, designed specifically for the treatment of CCM. The mid-stage study is being conducted at multiple centers, where patients have been randomly assigned to different groups to test the safety and effectiveness of REC-994.
The primary endpoint of the study is to assess the safety and tolerability of the candidate by measuring adverse events.
The secondary endpoint is to determine the effectiveness of REC-994 by considering feedback from both doctors and patients, conducting imaging tests to measure the number, size and changes in CCM lesions, studying the impact of acute stroke and exploring different biomarkers. These comprehensive assessments will provide valuable insights about REC-994’s potential as a treatment for CCM.
CCM is a neurovascular disorder triggered by genetic mutations, either inherited or acquired, impacting the functions of endothelial cells. The disease is marked by weak and thin blood vessel walls that can result in blood leakage into the surrounding brain or spinal cord tissue. This leakage can cause damage to the nearby brain tissue and result in persistent neurological issues. In rare instances, a more severe bleeding episode can lead to a stroke or even death.
Shares of Recursion have risen 28.9% year to date against the industry’s 1.3% decline.
Image Source: Zacks Investment Research
If successfully developed, REC-994 will have a market to address approximately 360,000 patients in Europe and the United States.
REC-994 has been granted the Orphan Drug designation for CCM by the FDA and the European Commission. This designation provides the company with additional market exclusivity and expedited regulatory paths.
Recursion’s other clinical studies include REC-2282 and REC-4881 for the potential treatment of neurofibromatosis and familial adenomatous polyposis, respectively. Both candidates are currently in the mid-stage clinical study.
Recursion Pharmaceuticals, Inc. Price and Consensus
Recursion Pharmaceuticals, Inc. price-consensus-chart | Recursion Pharmaceuticals, Inc. Quote
Zacks Rank and Stocks to Consider
Recursion currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Akero Therapeutics (AKRO - Free Report) , ADMA Biologics, Inc. (ADMA - Free Report) and Omega Therapeutics , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Loss per share estimate for Akero Therapeutics has narrowed from $3.46 to $2.80 for 2023 in the past 90 days. Shares of Akero Therapeutics have risen 3.8% year to date.
AKRO’s earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 7.96%.
Loss per share estimate for ADMA Biologics has narrowed from 19 cents to 9 cents for 2023 in the past 90 days. Shares of ADMA Biologics have nosedived 3.1% year to date.
ADMA’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.13%.
Loss per share estimate for Omega Therapeutics has narrowed from $2.51 to $2.05 for 2023 in the past 90 days. Shares of the company have risen 41.8% year to date.
OMGA’s earnings beat estimates in two of the trailing four quarters, met the mark in one and missed in another, delivering an average surprise of 8.24%.